Suggested remit: To appraise the clinical and cost effectiveness of guselkumab within its marketing authorisation for treating moderately to severely active Crohn’s disease.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6238

Project Team

Project lead Jennifer Upton

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Timeline

Key events during the development of the guidance:

Date Update
06 September 2024 Following completion of the scoping process and the NICE Medicines Optimisation Team briefing, it has been confirmed that this appraisal will be routed to the cost comparison process. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-January 2025 when we will write to you about how you can get involved.
21 August 2024 This topic has been rescheduled to align with regulatory timelines. This topic will now follow the cost comparison route, with a new Invitation To Participate to be sent out early next year.
21 August 2024 This topic has been rescheduled to align with regulatory timelines. This topic will now follow the cost comparison route, with a new Invitation To Participate to be sent out early next year.
30 July 2024 Invitation to participate
30 July 2024 Invitation to participate
07 May 2024 - 05 June 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6238
07 May 2024 In progress. Scoping commencing
18 January 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual